Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H32O6 |
Molecular Weight | 416.5073 |
Optical Activity | UNSPECIFIED |
Additional Stereochemistry | Yes |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
Stereo Comments | AXIAL, R |
SHOW SMILES / InChI
SMILES
COC1=C(OC)C(OC)=C2C(C[C@H](C)[C@H](C)CC3=CC(OC)=C(OC)C(OC)=C23)=C1
InChI
InChIKey=JEJFTTRHGBKKEI-OKILXGFUSA-N
InChI=1S/C24H32O6/c1-13-9-15-11-17(25-3)21(27-5)23(29-7)19(15)20-16(10-14(13)2)12-18(26-4)22(28-6)24(20)30-8/h11-14H,9-10H2,1-8H3/t13-,14+
Molecular Formula | C24H32O6 |
Molecular Weight | 416.5073 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Schisandrin A is a bioactive lignan occurring in the fruits of plants of the Schisandra genus that have traditionally been used in Korea for treating various inflammatory diseases. Schisandrin A inhibits dengue viral replication via upregulating antiviral interferon responses through STAT signaling pathway. Schisandrin A represents a potential antiviral agent to block DENV replication in vitro and in vivo. Schisandrin A has been widely reported as being very effective for the treatment of liver disease. The hepatoprotective mechanisms of schisandrin A may include activation of autophagy flux and inhibition of apoptosis.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL613966 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28338050 |
28.1 µM [EC50] | ||
Target ID: CHEMBL1287617 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26084208 |
|||
Target ID: CHEMBL3542435 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26084208 |
|||
Target ID: CHEMBL1697668 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25975095 |
|||
Target ID: CHEMBL3622 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24855828 |
86.41 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28875271 |
Primary | Unknown Approved UseUnknown |
||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21895978
Male Sprague-Dawley rats were intragastrically administered with varied doses of Schisandrin A (8 mg/kg or 16 mg/kg or 32 mg/kg) or 75 mg/kg ketoconazole for three consecutive days.
Route of Administration:
Intragastric
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28338050
The DENV-infected Huh-7 cells were treated with 30 or 40 uM of schisandrin A for 3 days. The RT-qPCR results revealed that schisandrin A can block the replication of the four serotypes of
DENV in a concentration-dependent manner.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:09:10 GMT 2023
by
admin
on
Sat Dec 16 11:09:10 GMT 2023
|
Record UNII |
74XQL5DO3S
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB180108
Created by
admin on Sat Dec 16 11:09:10 GMT 2023 , Edited by admin on Sat Dec 16 11:09:10 GMT 2023
|
PRIMARY | |||
|
155256
Created by
admin on Sat Dec 16 11:09:10 GMT 2023 , Edited by admin on Sat Dec 16 11:09:10 GMT 2023
|
PRIMARY | |||
|
61281-38-7
Created by
admin on Sat Dec 16 11:09:10 GMT 2023 , Edited by admin on Sat Dec 16 11:09:10 GMT 2023
|
PRIMARY | |||
|
74XQL5DO3S
Created by
admin on Sat Dec 16 11:09:10 GMT 2023 , Edited by admin on Sat Dec 16 11:09:10 GMT 2023
|
PRIMARY | |||
|
Deoxyschizandrin
Created by
admin on Sat Dec 16 11:09:10 GMT 2023 , Edited by admin on Sat Dec 16 11:09:10 GMT 2023
|
PRIMARY | |||
|
100000175517
Created by
admin on Sat Dec 16 11:09:10 GMT 2023 , Edited by admin on Sat Dec 16 11:09:10 GMT 2023
|
PRIMARY | |||
|
DTXSID20976773
Created by
admin on Sat Dec 16 11:09:10 GMT 2023 , Edited by admin on Sat Dec 16 11:09:10 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
USP
|